Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Cellectis currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 3 distinct art units, showing a range of examiner perspectives within a set of 3 distinct art units. This distribution suggests that while the company's technology is concentrated in 3 distinct art units, it is being reviewed by a wide variety of individuals.
KIM, TAEYOON is the busiest examiner with 1 busiest examiner pending action. Since each of the 6 pending office actions is assigned to a different examiner, the company must manage 6 distinct examiners. Even though the 3 distinct art units suggest some technical overlap in the subject matter, the fact that there are 6 distinct examiners means that no examiner's preferences will dominate the company's overall prosecution experience.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 5 (83%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| COLLINS, CYNTHIA E | 1 | 82.2% | +9.0% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| ZHONG, WAYNESHAOBIN | 1 | 72.2% | +21.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18737469 | METHODS FOR NON-TRANSGENIC GENOME EDITING IN PLANTS | COLLINS, CYNTHIA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297770 | CANOLA WITH HIGH OLEIC ACID | ZHONG, WAYNESHAOBIN | 60d overdue |
| 18914680 | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION | KIM, TAEYOON | — |
| 18607387 | INHIBITORY CHIMERIC ANTIGEN RECEPTORS | BRISTOL, LYNN ANNE | — |
| 18530878 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | NGUYEN, QUANG | — |
| 18451816 | CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | HUYNH, PHUONG N | — |
| Art Unit | Apps |
|---|---|
| 1662 | 2 |
| 1631 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18914680 | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION | KIM, TAEYOON | — | §103§112DP | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18737469 | METHODS FOR NON-TRANSGENIC GENOME EDITING IN PLANTS | COLLINS, CYNTHIA E | 1662 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18607387 | INHIBITORY CHIMERIC ANTIGEN RECEPTORS | BRISTOL, LYNN ANNE | — | §112DP | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18530878 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | NGUYEN, QUANG | 1631 | §102§103§112DP | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18451816 | CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | HUYNH, PHUONG N | 1641 | §112DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18297770 | CANOLA WITH HIGH OLEIC ACID | ZHONG, WAYNESHAOBIN | 1662 | §102§103§112DP | Final Rejection | 60d overdue | Pending | Apr 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial